Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Trial Details

NCT ID

NCT07266493

Phase

PHASE2

Sponsor

Shanghai Zhongshan Hospital

Status

RECRUITING

Cancer Type

Esophageal Cancer

Interventions

• Chemotherapy （Albumin bound paclitaxel and Carboplatin）

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• The subjects voluntarily joined this study, were able to sign the informed consent form, and had good compliance;
• Age ≥ 18 years old (when signing the informed consent form);
• ECOG score 0-1 points;
• Diagnosed with operable esophageal squamous cell carcinoma through pathological diagnosis (pathological tissue/cytology) and imaging;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.